J&J Unit Strikes $3.7B Hepatitis B Gene Therapy Deal
Johnson & Johnson subsidiary Janssen Pharmaceuticals Inc. on Thursday struck a deal with Arrowhead Pharmaceuticals Inc. worth as much as $3.7 billion to help develop and commercialize a gene therapy candidate...To view the full article, register now.
Already a subscriber? Click here to view full article